Almog Yaniv, Novack Victor, Eisinger Miruna, Porath Avi, Novack Lena, Gilutz Harel
Medical Intensive Care Unit, Soroka University Medical Center, Beer-Sheva, Israel.
Crit Care Med. 2007 Feb;35(2):372-8. doi: 10.1097/01.CCM.0000253397.42079.D5.
Statins have pleiotropic effects that are independent of their lipid-lowering ability. We have previously shown that prior statin therapy is associated with a decreased risk of severe sepsis in patients admitted with acute bacterial infection. The aim of this study was to determine whether statin therapy is associated with a decreased risk of infection-related mortality.
A prospective, observational, population-based study.
Tertiary university medical center.
Using a computerized database, 11,490 patients with atherosclerotic diseases were identified and followed for up to 3 yrs. Two groups of patients were compared: those receiving statins in the final month before follow-up termination and those who were not.
None.
The primary outcome was infection-related mortality. Of the 11,362 patients included in the final analysis, 5,698 (50.1%) belonged to the statin group. Median follow-up was 19.8 months (interquartile range, 14.3-33.3). The risk of infection-related mortality was significantly lower in the statin compared with the no-statin group (0.9% vs. 4.1%), reflecting a relative risk of 0.22 (95% confidence interval, 0.17-0.28). Stepwise Cox proportional hazard survival analysis including a propensity score for receiving statins revealed that the protective effect of statins adjusted for all known potential confounders remained highly significant (hazard ratio, 0.37; 95% confidence interval, 0.27-0.52).
Therapy with statins may be associated with a reduced risk of infection-related mortality. This protective effect is independent of all known comorbidities and dissipates when the medication is discontinued. If this finding is supported by prospective controlled trials, statins may play an important role in the primary prevention of infection-related mortality.
他汀类药物具有多种效应,这些效应独立于其降脂能力。我们之前已经表明,既往他汀类药物治疗与急性细菌感染入院患者严重脓毒症风险降低相关。本研究的目的是确定他汀类药物治疗是否与感染相关死亡率降低相关。
一项前瞻性、观察性、基于人群的研究。
三级大学医学中心。
使用计算机化数据库,识别出11490例动脉粥样硬化疾病患者,并随访长达3年。比较两组患者:在随访终止前最后一个月接受他汀类药物治疗的患者和未接受治疗的患者。
无。
主要结局是感染相关死亡率。在最终分析纳入的11362例患者中,5698例(50.1%)属于他汀类药物组。中位随访时间为19.8个月(四分位间距,14.3 - 33.3)。与未使用他汀类药物组相比,他汀类药物组感染相关死亡率显著更低(0.9%对4.1%),相对风险为0.22(95%置信区间,0.17 - 0.28)。逐步Cox比例风险生存分析包括接受他汀类药物的倾向评分,结果显示,在调整所有已知潜在混杂因素后,他汀类药物的保护作用仍然非常显著(风险比,0.37;95%置信区间,0.27 - 0.52)。
他汀类药物治疗可能与感染相关死亡率降低风险相关。这种保护作用独立于所有已知合并症,且停药后消失。如果这一发现得到前瞻性对照试验的支持,他汀类药物可能在感染相关死亡率的一级预防中发挥重要作用。